Microbiologists form NGO Microgen patented a novel symptom-modifying drug product which has no analogues on the Russian market.

17.08.2015
In 2014, the sales of injectable symptom-modifying drug product in Russia amounted to about 4.5 billion rubles. Generally, such products arer represented by Romanian an German manufacturers.

The Ufa branch of NGO Microgen developed a unique technology of effective post-treatment of an aqueous solution of the active substance of a symptom-modifying drug product Chondrolon-Pro intended for the treatment of degenerative diseases of the peripheral synovial joints and spine.

According to the authors of the project, in contrast to other injectable chondroprotechtors containing various preservatives that are organic, organometallic or inorganic, Chondrolon-Pro from Ufa has stable physical and chemical properties and no extra antimicrobial preservatives that may be toxic during long-term storage which is 3 years.

Moreover, serial biotechnological operations allowed to obtain samples with improved quality, stable therapeutic effect and high safety. Therapeutic effects of chondroitin sulphate and L-proline on the affected joints and spine enhances regenerative effect of Chondrolon-Pro.

The manufacturing technology is patented as the following invention: "The method for manufacturing highly purified injectable form of a drug product for the treatment of degenerative musculoskeletal diseases."

Let us note that Chondrolon-Pro refers to the group of symptom-modifying drug products. This product for intramuscular or intra-articular administration inhibits the activity of enzymes that cause the degradation of articular cartilage, increases metabolism, has anti-inflammatory effect, improves the production of joint fluid. The result of this action is the elimination or significant reduction in the intensity of joint pain and functional recovery of the musculoskeletal system.

According to the World Health Organization, 30 to 87% of the population 30 to 60 years old suffer from osteochondrosis. This common condition accounts for 20 to 80% of cases of temporary disability. Degenerative disorders of the peripheral joints affects about 15 million in Russia. 

Industrial production of the novel product will be launched immediately after the end of clinical trials.